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Mike ClarkeAbstract
Six years after the launch of Systematic Reviews by Biomed Central, this article is part of the celebration of the
journal. It contains personal reflections on the past, present and future of systematic reviews, using examples
relevant to the role of systematic reviews in cataloguing and analysing research, assessing quality and planning
new studies. The focus is on the most common of the various types of systematic review in health and social care,
namely those assessing the effects of interventions.Background
Shortly before the start of the twentieth century, George
Gould presented a vision to the inaugural meeting of the
Association of Medical Librarians in Philadelphia on
May 2, 1898: “I look forward to such an organisation of
the literary records of medicine that a puzzled worker in
any part of the civilized world shall in an hour be able to
gain a knowledge pertaining to a subject of the experi-
ence of every other man in the world” [1].
Now, 120 years on, 114 years since Karl Pearson
published a pooled analysis of the results of a series of
studies to investigate the effects of a typhoid vaccine [2],
42 years since Gene Glass coined the term “meta-analysis”
[3], 25 years since the Cochrane Collaboration (now,
simply, Cochrane) was established, and 6 years since the
journal Systematic Reviews began, I am pleased to be part
of the journal’s celebration and to share my thoughts on
the history of this type of research, which was recently
described as entering a “midlife crisis” [4]. It is a history
that the journal has helped to document, publishing
research articles for many aspects of the methods for
systematic reviews, which are likely to feature in historical
accounts now and far into the future.
It is, of course, strange to be writing about the history
of something that is living, growing and changing, and
of which I feel very much part. However, finding myself
increasingly using the phrase “years ago” when talking
about projects I have been involved in, some of what hasCorrespondence: m.clarke@qub.ac.uk
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historical, as I reflected in an essay for the James
Lind Library [5].
Many people have said that history belongs to the
victors and to some extent that is the case when we look
back at what have become known as “systematic
reviews” over the last century and more. But, I suggest
that there is also an important role for the persistent, for
those who have stuck at the task despite the challenges.
For people involved in systematic reviews, recent de-
cades have seen some of these challenges be overcome.
Many tasks are now much easier for people preparing
and using systematic reviews than even 10 years ago be-
cause of the persistence of individuals and organisations
who have raised the profile, importance and value of
systematic reviews. Initiatives that are now evolving and
developing have come from that persistence and are
likely to be seen as pivotal to those writing historical
pieces in years and decades to come. I look at some of
these areas in this article, helped by other accounts of
the history of evidence synthesis [4–8].
I have not attempted to conduct my own “systematic
review” of the history. Instead, I illustrate this history
with examples relevant to the past, present and future,
anchored around some of the key reasons for doing
systematic reviews today. My main attention is on the
role of systematic reviews in cataloguing and analysing
research, but I also touch on their importance for
assessing quality and planning new studies. I focus on
the commonest type of systematic review in health and
social care, those that assess the effects of interventions.
Although many of the principles for doing these reviewsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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evolving and a historian even just a few years from now
may be looking back on a different landscape. They may
be reflecting on even greater growth in the number of
reviews that have been conducted as “rapid reviews”
become more common as a means to quickly meet the
specific needs of decision makers who do not wish to
wait for a full systematic review. Rapid reviews speed up
the processes for searching, appraisal, extraction and
gathering of data extraction, and the analysis and synthe-
sis of the findings of the included studies [9, 10]. And, in
a further development, the concept of “living systematic
reviews” has been introduced to refer to reviews where
the updating process is almost continuous, adding new
studies as soon as possible after they become available
[11]. These accelerations may lead to bias, and analyses
of their advantages and disadvantages compared to full
reviews are likely to either confirm that things can be
done quicker without compromising quality or instil
caution in those users who feel that they cannot wait for
a full review.
In recognition of how I am writing about a history that
is itself “living”, and how I expect I have failed to refer
to some key people, papers and developments, I
welcome comment, feedback and debate on how my
reflections match those of others who were, are and will
be part of the past, present and future of systematic
reviews.
Cataloguing
One of the challenges facing anyone wishing to use the
enormous amount of research that has been conducted
in health and social care, and the dozens or, sometimes
even, hundreds of individual studies addressing the same
issue is finding this material. In 1994, Cindy Mulrow
estimated that more than two million articles were being
published in biomedicine every year and drew a mental
picture of a tower 500 m high if all the journals were
piled on top of each other [12]. Since then, the arrival
and proliferation of online-only journals means that we
might no longer share the concept of piles of print
journals towering into the sky or occupying kilometres
of library shelves, and have moved on to thinking about
the number of terabytes of storage needed to cope with
all of these articles. However, the growth in the number
of articles has accelerated and many more than two
million articles are now published every year. Thinking
only of research that evaluates the effects of health and
social care interventions, tens of thousands of controlled
trials are published annually and more than 120,000
trials are currently open to recruitment according to a
search of the World Health Organization’s International
Clinical Trials Registry Platform [13] in August 2018
(apps.who.int/trialsearch).Systematic reviews help users to find their way
through this morass to the studies that they are most
interested in, and global efforts to facilitate systematic
reviews have greatly facilitated access to the individual
studies over the last few decades. In the 1970s, Archie
Cochrane wrote “It is surely a great criticism of our pro-
fession that we have not organised a critical summary,
by speciality or subspeciality, adapted periodically, of all
relevant randomised controlled trials” [14]. And, when
setting out one of the challenges to be overcome by The
Cochrane Collaboration in a British Medical Journal
editorial in 1992, Iain Chalmers, Kay Dickersin and Tom
Chalmers wrote “failing to conduct systematic, up to
date reviews of controlled trials of health care may result
in substantial adverse consequences for patients, practi-
tioners, the health services, researchers, and research
funding bodies” [15].
Of course, individual examples of such catalogues of
critical summaries of research exist from well before the
late twentieth century, but these were focused on spe-
cific topics. Most notably perhaps, James Lind’s treatise
on scurvy in the eighteenth century included not only
his own experiments on ways to prevent this disease but
also his “critical and chronological view of what has been
published on the subject” [16].
Systematic reviews today provide a valuable resource
as a catalogue of the studies addressing the specific
question for the review, but even without the reviews
themselves, much has been done to bring those studies
together. When The Cochrane Collaboration was estab-
lished in 1993, approximately 20,000 reports of rando-
mised trials could be easily found in the bibliographic
database, MEDLINE. Through improved indexing and
initiatives such as the MEDLINE retagging projects of
the US and UK Cochrane Centres [17], this has now in-
creased to more than 460,000 PubMed records tagged
with the publication type for “randomized controlled
trial” in August 2018. Nearly 60,000 of these were pub-
lished before 1992 and can now be found with this sim-
ple search. The Cochrane Central Register of Controlled
Trials itself now contains more than one million records,
and prospective registries of trials which were called for
in 1986 by John Simes [18] allow users to find both on-
going studies and many more that have closed. However,
the findings of many of these studies have not been
published [19], highlighting how this problem of
selective reporting, called “scientific misconduct” by Iain
Chalmers in 1990 [20], is ongoing.
Systematic reviews themselves are now in need of
similar cataloguing exercises. Reviews are more readily
retrievable in bibliographic databases than they were a
few decades ago, but are increasing rapidly in number.
Estimates for published reviews have risen from a total
of about 3000 in MEDLINE for the whole of the period
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in 2007 [22], through 4000 for 2010 [23] and towards
8000 for 2014 [24]. An August 2018 search of
PubMed for records tagged with the publication type
meta-analysis retrieved more than 11,000 records for
publications from 2017 in that database alone, and
Jessica Gurevitch et al. have estimated that the total
available in the literature is already beyond 200,000 [4].
There are also collections of systematic reviews
produced to a common standard, with an early exemplar
being the dozens of systematic reviews of controlled
trials relevant to maternity care brought together in the
1980s in Effective Care in Pregnancy and Childbirth [25],
which evolved into The Cochrane Collaboration Preg-
nancy and Childbirth Database [7]. Today, we have the
output produced by organisations such as Cochrane
(www.CochraneLibrary.com), Campbell (www.campbell-
collaboration.org/library.html) and the Joanna Briggs
Institute JBI (lww.com/jbisrir/Pages/default.aspx).
There are also aggregators of systematic reviews,
including the now archived Database of Abstracts of
Reviews of Effects (DARE) for the effects of healthcare
interventions generally (www.crd.york.ac.uk/CRDWeb),
and smaller collections such as that produced by
Evidence Aid to improve access to reviews relevant to
the humanitarian sector (www.EvidenceAid.org) [26].
There is even a dedicated prospective register for sys-
tematic reviews, PROSPERO. In fact, the second article
in Systematic Reviews in February 2012 presented the
“nuts and bolts” of this new register [27]. A total of 200
reviews were registered in PROSPERO’s first 8 months,
and it was warmly welcomed by Sally Davies, Director of
the UK’s National Institute for Health Research [28]. By
August 2018, nearly 40,000 ongoing reviews had been
registered, growing by more than 10,000 per year, and
methodology research is beginning to appear which uses
these records [29, 30]. Finally, individual reviews
themselves are now being subject to combination in
overviews bringing together the findings of multiple
reviews [31] and greater automation in the review process
looks set to accelerate further both the number of reviews
and the speed with which they are done [32–34].
Analysing
In 1885, Lord Rayleigh told the meeting of the British
Association for the Advancement of Science: “If, as is
sometimes supposed, science consisted in nothing but
the laborious accumulation of facts, it would soon come
to a standstill, crushed, as it were, under its own weight.
The suggestion of a new idea, or the detection of a law,
supersedes much that has previously been a burden on
the memory, and by introducing order and coherence
facilitates the retention of the remainder in an available
form. Two processes are thus at work side by side, thereception of new material and the digestion and assimi-
lation of the old. One remark, however, should be made.
The work which deserves, but I am afraid does not
always receive, the most credit is that in which discovery
and explanation go hand in hand, in which not only are
new facts presented, but their relation to old ones is
pointed out” [35].
When this combination of the old and the new is
achieved using quantitative methods, we enter the realm
of meta-analysis, the statistical combination of the
results of related studies. In their recent account of the
history of meta-analysis, which has a particular focus on
its use over the last three decades in ecology, evolution-
ary biology and conservation, Gurevitch et al. described
two different goals for those doing meta-analyses: a
specific one of assessing the evidence for the effects of
specific interventions or exposures for a particular prob-
lem or a more comprehensive one that seeks broad gener-
alisations across large numbers of study outcomes [4].
The term meta-analysis was coined by Gene Glass in
the mid-1970s and used in his American Educational
Research Association presidential address in April 1976,
describing it as “the analysis of analyses” [3]. The follow-
ing year, with Mary Lee Smith, Glass published one of
the largest meta-analyses, using data from 375 studies of
psychotherapy and counselling, with a total of more than
25,000 people [36], providing an example of the type of
comprehensive approach described by Gurevitch et al.
[4]. Around the same time, pivotal papers on the statis-
tical methods for combining the results of studies to
assess the more specific effects they describe, were being
published [37, 38]. Since then, as the statistical methods
have developed, so have the means for displaying the
results, with the introduction of the forest plot in the
1980s [39–41].
Looking to the future, some of the more advanced
statistical techniques seem set to become more com-
mon. These include methods such as the re-analysis of
the individual participant data from each included study
[42, 43], which was used as far back as 1970 [44] and is
likely to be boosted by greater access to the data from
trials [45, 46], while the more recent introduction of the
mixed treatment comparison or network meta-analyses
approach [47] has seen a large rise in the number of
published systematic reviews using this technique, with
several hundred now available [48–51].
Assessing quality and designing new studies
In 1753, Lind introduced his cataloguing of studies of
scurvy and the need for their appraisal with “As it is no
easy matter to root out prejudices,….it became requisite
to exhibit a full and impartial view of what had hitherto
been published on the scurvy … Indeed, before the
subject could be set in a clear and proper light, it was
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Unfortunately, to this day, systematic reviews continue
to face the problem that much of the existing research is
“rubbish” or non-existent. A large proportion of Cochrane
Reviews conclude that there is insufficient reliable
evidence to determine whether there are important
differences in the effects of the interventions they seek to
compare.
The last couple of decades have seen historical
developments in the assessment of the quality of existing
research, leading to greater transparency in the process
but also greater concerns about the amount of research
waste due to poor-quality studies [52]. The Cochrane
Risk of Bias tools for randomised [53] and non-
randomised trials [54] allow reviewers to show their
users how they reached their decisions, while the work
of GRADE and GRADE-CERQual provides the means to
present both the quality of the evidence brought
together in the review and the strength of its recommen-
dations [55–57]. We are also equipped to assess the
quality of systematic reviews, developing from the
original Oxman and Guyatt checklist [58] to two
incarnations of AMSTAR [59, 60] for systematic reviews
generally and checklists for specific types of review such
as that from ISPOR for network meta-analyses [61].
There is also the QUOROM [62], now PRISMA guid-
ance for reporting reviews [63], with extensions for re-
views using individual participant data [64] and network
meta-analysis [65]. However, application of these tools
reveals that much work needs to be done to improve the
quality of many systematic reviews [66, 67].
Given how many systematic reviews reach conclusions
that reflect the inability of the existing evidence base to
answer their research question and highlight the need
for ongoing uncertainty about the relative effects of the
interventions they investigated, one of the important
benefits for systematic reviews is in providing the justifi-
cation for the new studies that will fill this gap. Some of
the early examples of systematic reviews recognised this.
In 1976, Shaikh et al. reviewed 29 studies of tonsillec-
tomy and adenoidectomy in children that had been pub-
lished over the preceding 50 years and concluded by
calling for a new, high-quality randomised trial that
would ensure that “the methodologic pitfalls annotated
in our review be guarded against” [68]. Reading the
implications for research in more recent systematic
reviews, one would see many similar calls [69]. Drawing
on the past while looking to the future, these new
studies need to be designed in the light of the existing
evidence [70], report their findings in the context of the
updated evidence [71, 72] and use methods that will
minimise research waste [52, 73]. In doing so, these new
studies will feed into future systematic reviews, and their
conduct and that of the future systematic reviews willalso be able to draw on another of the recent historical
developments in systematic reviews: the systematic
review of methodology [74]. The aforementioned rapid
review process may also be of particular relevance here,
as a means to quickly identify research gaps and uncer-
tainties. “Rapid Research Needs Assessments” can high-
light those areas most in need of a new study and the
UK’s Public Health Rapid Support Team for disease out-
breaks plans to work with Evidence Aid [26] to conduct
such assessments in the early stages of a humanitarian
emergency associated with a disease outbreak in order
to identify important uncertainties that could be tackled
by initiating new research.
Conclusions
Returning to the nineteenth century quote from George
Gould, with which I began this article, we now live in a
world where technology means that people everywhere
should be able to retrieve the knowledge they need
about the effects of health and social care interventions
in minutes, as long as barriers are not put in their way
to access this [75]. If this knowledge is to be reliable and
to have minimised bias, it will need to have been
accumulated in systematic reviews. The last century and
more, but particularly recent decades, have seen sub-
stantial developments to assist with this. Some of these
can already be recognised as “historical”, others will
become so in the years to come, and others will fade
away. However, the ongoing persistence of those wishing
to provide the evidence to help people making decisions
and choices about their own health and social care, and
that of others, will, I hope, ensure that systematic
reviews will continue to have a future, as well as a past.
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